NeurogesX To Present At BioCentury Future Leaders In The Biotech Industry Conference
SAN MATEO, Calif., April 1 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the BioCentury Future Leaders in the Biotech Industry Conference 2010, to be held Thursday, April 8, 2010 at the Millennium Broadway Hotel & Conference Center in New York, New York.
Mr. DiTonno and Stephen Ghiglieri, Executive Vice President, Chief Operating Officer and Chief Financial Officer, will be available to respond to questions during a breakout session immediately following the presentation, and to participate in one-on-one meetings with investors attending the conferences.
Event: BioCentury Future Leaders in the Biotech Industry Conference 2010
Date: Thursday, April 8, 2010Time: 2:30pm ET (Breakout: 3:00-4:00pm ET) Place: The Millennium Broadway Hotel & Conference Center, New York, NY (Room 508) The presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at www.neurogesx.com. The webcast will be archived for 90 days. NASDAQ Opening Bell Ceremony: April 6, 2010 Mr. DiTonno, along with members of the NeurogesX management and sales teams, will ring the ceremonial market opening bell at the NASDAQ Stock Market at 9:30 a.m. ET on Tuesday, April 6, 2010. A live webcast of the NASDAQ opening bell will be available at: http://www.nasdaq.com/reference/marketsite_events.stm, where it will be archived for one year. About NeurogesX, Inc. NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept and is now poised to bring its lead product to patients and physicians. In addition, we continue to apply our knowledge and expertise in the development of other novel treatments for pain. The Company's lead product, Qutenza® (capsaicin) 8% patch, is a localized dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union. NeurogesX expects to launch Qutenza in United States in April 2010 for patients with postherpetic neuralgia (PHN). In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc. The Company's most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.